|
Overview
of ICH Q8 and Q9
Andy Townsend, AstraZeneca |
|
Public
Standards for Pharmaceutical analysis: A USP Perspective
Shawn Dressman, USP |
|
Application
of the Principles of Quality by Design to Analytical Methods
Phil Borman & Marion Chatfield, GSK |
|
Raman
Optical Activity and its uses in the Pharmaceutical Industry
Prof George Tranter, Chiral Labs |
|
ICH
Q10 - Pharmaceutical Quality System
Neil Wilkinson, AstraZeneca |
|
Lab
on a chip for pi measurements
Arthur Watson, Convergent |
|
BMS
Perspective on Drug Product forced Degradation Studies
Adele Patterson, BMS |
|
Rapid
identification and quantification of post translational
modifications by UPLC
Anna Izzo, Merck Serono |
|
Forced
Degradation Studies: A perspective on Inhalation Products
Nicola Gillott, 3M |
|
Rapid
HPLC Methods
Mike Davies, Lonza |
|
Practical
Approaches to conducting forced degradation studies
Keith Parker, AstraZeneca |
|
PQRI
Sulphonate Ester Investigations - PASG Spring 2007 update |
|
The
Role of Dissolution in Quality by Design
Dónal Murphy, AstraZeneca |
|
Validation
of CE/LC/MS coupled methods for improved Micro-heterogeneity
discrimination.
Paula Vickers, LGC |
|
Designing
a Quality Dissolution Method
Terry Way, USP |
|
Monitoring
Post Translational Modifications by CD and IR
Marco Barba, University of Roma III, Italy |
|
Solid
State NMR in Pharmaceutical Development
Les Hughes, AstraZeneca |
|
|
|
PASG
Future Objectives
Gareth Pearce, MSD |
|
|
|
|
|
